Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2′-O-methyl RNA, phosphorothioates and small interfering RNA

Nucleic Acids Research

Volumn 31, Issue 12, 2003, Pages 3185-3193

  Grünweller, Arnold ^a   Wyszko, Eliza ^a,b   Bieber, Birgit ^a   Jahnel, Ricarda ^a   Erdmann, Volker A ^a   Kurreck, Jens ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b INSTITUTE OF BIOORGANIC CHEMISTRY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

2' O METHYL RNA; ANTISENSE OLIGONUCLEOTIDE; CHIMERIC PROTEIN; DNA; DOUBLE STRANDED RNA; FOMIVIRSEN; GREEN FLUORESCENT PROTEIN; LOCKED NUCLEIC ACID; MONOMER; NUCLEIC ACID; PHOSPHOROTHIOIC ACID DERIVATIVE; RNA DERIVATIVE; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VANILLOID RECEPTOR; VANILLOID RECEPTOR 1; DRUG RECEPTOR; HYBRID PROTEIN; NUCLEOTIDE; PHOTOPROTEIN;

ANIMAL CELL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG STABILITY; DRUG TARGETING; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; IC 50; IMMUNOBLOTTING; IN VIVO STUDY; MAMMAL CELL; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; ANIMAL; CELL STRAIN COS1; CHEMISTRY; COMPARATIVE STUDY; GENE EXPRESSION; GENE SILENCING; GENETICS; METABOLISM; METHYLATION;

ANIMALIA; MAMMALIA;

ANIMALS; COS CELLS; GENE EXPRESSION; GENE SILENCING; GREEN FLUORESCENT PROTEINS; INHIBITORY CONCENTRATION 50; LUMINESCENT PROTEINS; METHYLATION; NUCLEIC ACIDS; OLIGONUCLEOTIDES, ANTISENSE; OLIGORIBONUCLEOTIDES, ANTISENSE; RECEPTORS, DRUG; RECOMBINANT FUSION PROTEINS; RNA, SMALL INTERFERING; THIONUCLEOTIDES; TRANSFECTION;

EID: 0038578021     PISSN: 03051048     EISSN: None     Source Type: Journal    
DOI: 10.1093/nar/gkg409     Document Type: Article

References (44)

1. Crooke,S.T. (2000) Progress in antisense technology: the end of the beginning. Methods Enzymol., 313, 3-45.
2. Phillips,M.I. and Zhang,Y.C. (2000) Basic principles of using antisense oligonucleotides in vivo. Methods Enzymol., 313, 46-56.
3. Stein,C.A. (2001) The experimental use of antisense oligonucleotides: a guide for the perplexed. J. Clin. Invest., 108, 641-64.
4. Dove,A. (2002) Antisense and sensibility. Nat. Biotechnol., 20, 121-124.
5. Marwick,C. (1998) First 'antisense' drug will treat CMV retinitis. J. Am. Med. Assoc., 280, 871.
6. Eckstein,F. (2000) Phosphorothioate oligodeoxynucleotides: what is their origin and what is unique about them? Antisense Nucleic Acid Drug Dev., 10, 117-121.
7. Brown,D.A., Kang,S.H., Gryaznov,S.M., DeDionisio,L., Heidenreich,O., Sullivan,S., Xu,X. and Nerenberg,M.I. (1994) Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J. Biol. Chem., 269, 26801-26805.
8. Guvakova,M.A., Yakubov,L.A., Vlodavsky,I., Tonkinson,J.L. and Stein,C.A. (1995) Phosphorothioate oligodeoxynucleotides bind to basic fibroblast growth factor, inhibit its binding to cell surface receptors and remove it from low affinity binding sites on extracellular matrix. J. Biol. Chem., 270, 2620-2627.
9. Rockwell,P., O'Connor,W.J., King,K., Goldstein,N.I., Zhang,L.M. and Stein,C.A. (1997) Cell-surface perturbations of the epidermal growth factor and vascular endothelial growth factor receptors by phosphorothioate oligodeoxynucleotides. Proc. Natl Acad. Sci. USA, 94, 6523-6528.
10. Levin,A.A. (1999) A review of the issues in the pharmacokinetics and toxicology of phosphorothioate antisense oligonucleotides. Biochim. Biophys Acta, 1489, 69-84.
11. Agrawal,S. and Zhao,Q. (1998) Mixed backbone oligonucleotides: improvement in oligonucleotide-induced toxicity in vivo. Antisense Nucleic Acid Drug Dev., 8, 135-139.
12. Toulme,J.J. (2001) New candidates for true antisense. Nat. Biotechnol., 19, 17-18.
13. Braasch,D.A. and Corey,D.R. (2002) Novel antisense and peptide nucleic acid strategies for controlling gene expression. Biochemistry, 41, 4503-4510.
14. Kurreck,J. (2003) Antisense technologies: improvement through novel chemical modifications. Eur. J. Biochem., 270, 1628-1644.
15. Braasch,D.A. and Corey,D.R. (2001) Locked nucleic acid (LNA): fine-tuning the recognition of DNA and RNA. Chem. Biol., 8, 1-7.
16. Elayadi,A.N. and Corey,D.R. (2001) Application of PNA and LNA oligomers to chemotherapy. Curr. Opin. Invest. Drugs, 2, 558-561.
17. Ørum,H. and Wengel,J. (2001) Locked nucleic acids: a promising molecular family for gene-function analysis and antisense drug development. Curr. Opin. Mol. Ther., 3, 239-243.
18. Petersen,M. and Wengel,J. (2003) LNA: a versatile tool for therapeutics and genomics. Trends Biotechnol., 21, 74-81.
19. Kurreck,J., Wyszko,E., Gillen,C. and Erdmann,V.A. (2002) Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res., 30, 1911-1918.
20. Wahlestedt,C., Salmi,P., Good,L., Kela,J., Johnsson,T., Hokfelt,T., Broberger,C., Porreca,F., Lai,J., Ren,K., Ossipov,M., Koshkin,A., Jakobsen,N., Skouv,J., Oerum,H., Jacobsen,M.H. and Wengel,J. (2000) Potent and nontoxic antisense oligonucleotides containing locked nucleic acids. Proc. Natl Acad. Sci. USA, 97, 5633-5638.
21. Elayadi,A.N., Braasch,D.A. and Corey,D.R. (2002) Implications of high-affinity hybridization by locked nucleic acid oligomers for inhibition of human telomerase. Biochemistry, 41, 9973-9981.
22. Arzumanov,A., Walsh,A.P., Rajwanshi,V.K., Kumar,R., Wengel,J. and Gait,M.J. (2001) Inhibition of HIV-1 Tat-dependent trans activation by steric block chimeric 2′-O-methyl/LNA oligoribonucleotides. Biochemistry, 40, 14645-14654.
23. Braasch,D.A., Liu,Y. and Corey,D.R. (2002) Antisense inhibition of gene expression in cells by oligonucleotides incorporating locked nucleic acids: effect of mRNA target sequence and chimera design. Nucleic Acids Res., 30, 5160-5167.
24. Fluiter,K., ten Asbroek,L.M.A., de Wissel,M., Jakobs,M.E., Wissenbach,M., Olsson,H., Olsen,O., Oerum,H. and Baas,F. (2003) In vivo tumor growth inhibition and biodistribution studies of locked nucleic, acid (LNA) antisense oligonucleotides. Nucleic Acids Res., 31, 953-962.
25. Zamore,P.D. (2001) RNA interference: listening to the sound of silence. Nature Struct. Biol., 8, 746-750.
26. Sharp,P.A. (2001) RNA interference-2001. Genes Dev., 15, 485-490.
27. Hannon,G.J. (2002) RNA interference. Nature, 418, 244-251.
28. Stark,G.R., Kerr,I.M., Williams,B.R., Silverman,R.H. and Schreiber,R.D. (1998) How cells respond to interferons. Annu. Rev. Biochem., 67, 227-264.
29. He,Y and Katze,M.G. (2002) To interfere and to anti-interfere: the interplay between hepatitis C virus and interferon. Viral Immunol., 15, 95-119.
30. Elbashir,S.M., Harborth,J., Lendeckel,W., Yalcin,A., Weber,K. and Tuschl,T. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 411, 494-498.
31. McCaffrey,A.P., Meuse,L., Pham,T.T., Conklin,D.S., Hannon,G.J. and Kay,M.A. (2002) RNA interference in adult mice. Nature, 418, 38-39.
32. Xia,H., Mao,Q., Paulson,H. and Davidson,B.L. (2002) siRNA-mediated gene silencing in vitro and in vivo. Nat. Biotechnol., 20, 1006-1010.
33. Brummelkamp,T., Bernards,R. and Agami,R. (2002) Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell, 2, 243-247.
34. Montell,C., Birnbaumer,L. and Flockerzi,V. (2002) The TRP channels, a remarkably functional family. Cell, 108, 595-598.
35. Caterina,M.J., Schumacher,M.A., Tominaga,M., Rosen,T.A., Levine,J.D. and Julius,D. (1997) The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature, 389, 816-824.
36. Tominaga,M., Caterina,M.J., Malmberg,A.B., Rosen,T.A., Gilbert,H., Skinner,K., Raumann,B.E., Basbaum,A.I. and Julius,D. (1998) The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron, 21, 531-543.
37. Kurreck,J., Bieber,B., Jahnel,R. and Erdmann,V.A. (2002) Comparative study of DNA enzymes and ribozymes against the same full-length messenger RNA of the vanilloid receptor subtype I. J. Biol. Chem., 277, 7099-7107.
38. 't Hoen,P.A., Rosema,B.S., Commandeur,J.N., Vermeulen,N.P., Manoharan,M, van Berkel,T.J., Biessen,E.A. and Bijsterbosch,M.K. (2002) Selection of effective antisense oligodeoxynucleotides with a green fluorescent protein-based assay. Discovery of selective and potent inhibitors of glutathione S-transferase Mu expression. Eur. J. Biochem., 269, 2574-2583.
39. Saris,C.J., Domen,J. and Berns,A. (1991) The pim-1 oncogene encodes two related protein-serine/threonine kinases by alternative initiation at AUG and CUG. EMBO J., 10, 655-664.
40. Elbashir,S.M., Harborth,J., Weber,K. and Tuschl,T. (2002) Analysis of gene function in somatic mammalian cells using small interfering RNAs. Method, 26, 199-213.
41. Miyagishi,M. and Taira,K. (2002) U6 promotor-driven siRNA with four uridine 3′ overhangs efficiently suppress targeted gene expression in mammalian cells. Nat. Biotechnol., 20, 497-500.
42. Vickers,T.A., Koo,S., Bennett,C.F., Crook,S.T., Dean,N.M. and Baker,B.F. (2003) Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. J. Biol. Chem., 278, 7108-7118.
43. Amarzguioui,M., Holen,T., Babaie,E. and Prydz,H. (2003) Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res., 31, 589-595.
44. Bertrand,J.-R., Pottier,M., Vekris,A., Opolon,P., Maksimenko,A. and Malvy,C. (2002) Comparison of antisense oligonucleotides and siRNAs in cell culture and in vivo. Biochem. Biophys. Res. Commun., 296, 1000-1004.